Allakos Inc. (ALLK)
After hours:
| Previous close | 1.0300 |
| Open | 1.0600 |
| Bid | 1.1000 x 200 |
| Ask | 1.1600 x 100 |
| Day's range | 1.0500 - 1.1400 |
| 52-week range | 0.9800 - 5.6400 |
| Volume | |
| Avg. volume | 462,477 |
| Market cap | 98.284M |
| Beta (5Y monthly) | 0.91 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.4600 |
| Earnings date | 07 Aug 2024 - 12 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 2.90 |
GlobeNewswireAllakos Announces First Patient Dosed in Phase 1 Trial of AK006 in Chronic Spontaneous Urticaria
– Top-line Phase 1 CSU results expected at year end 2024 – SAN CARLOS, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a biotechnology company developing AK006 for the treatment of mast cell-driven diseases, today announced that the first patient with chronic spontaneous urticaria (CSU) has been dosed in a randomized, double-blind, placebo-controlled Phase 1 trial of AK006. The Phase 1 trial is designed to assess the safety, tolerability and pharmacokinetics of AK006, and t
- GuruFocus.com
Allakos Inc. Reports Increased Losses in Q1 2024, Misses Analyst Earnings Predictions
Detailed Analysis of Financial Performance and Future Outlook
- GlobeNewswire
Allakos Provides Business Update and Reports First Quarter 2024 Financial Results
SAN CARLOS, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today provided a business update and reported financial results for the first quarter ended March 31, 2024. Recent Allakos Events Completed dosing in the single ascending dose (SAD) cohorts and multiple ascending dose (MAD) cohorts of the randomized, double-blind, placebo-controlled
